<DOC>
	<DOCNO>NCT01793090</DOCNO>
	<brief_summary>The aim research investigate safety efficacy EPI-743 treatment patient Cbl-C defect relate visual neurological impairment . Primary Endpoints improvement visual function assess visual acuity eye-hand coordination manual dexterity . Secondary Endpoints improvement neurologic function , evaluate battery age-appropriated psychophysical test , and/or objective electrophysiological test Visual Evoked potential ( VEP ) Electroretinogram ( ERG ) and/or change serum marker redox state .</brief_summary>
	<brief_title>EPI-743 Cobalamin C Defect : Effects Visual Neurological Impairment</brief_title>
	<detailed_description>Cobalamin C ( Cbl-C ) defect common inborn error cobalamin metabolism cause methylmalonic aciduria homocystinuria . Cbl-Cdefect due impaired activity MMACHC , cobalamin trafficking protein , involve decyanation cyanocobalamin well dealkylation alkylcobalamins glutathione transferase activity . Despite pharmacological treatment hydroxycobalamin , betaine , folic acid , ( carnitine ) , long-term outcome early-onset patient case unsatisfactory progression visual neurological impairment , mainly express form retinal degeneration and/or maculopathy . Moreover , despite hypothesis propose , pathophysiological mechanism cause progressive eye brain damage still remain unclear . Recently , contribution oxidative stress hypothesize base vitro study show Cbl-C fibroblast significant increase reactive oxygen specie ( ROS ) vivo study document severe alteration glutathione specie , main cellular redox buffer . EPI-743 small molecule therapeutic demonstrate beneficial effect diseases characterized oxidative stress alteration glutathione redox balance include Leigh syndrome inherit respiratory chain disease . Based principle Cbl-C defect cause vivo vitro perturbation redox state , aim study verify potential beneficial effect EPI-743 preventing/reducing progression neurological visual sign , well ameliorate redox abnormality Cbl-C patient , combination standard therapy . Primary Endpoints include improvement visual function assess visual acuity eye-hand coordination manual dexterity . Secondary Endpoints improvement neurologic function , evaluate battery age-appropriated psychophysical test , and/or objective electrophysiological test VEP ERG , and/or change serum marker redox state . Patient 's parental Quality life regularly assess prior treatment start periodically EPI-743 .</detailed_description>
	<mesh_term>Homocystinuria</mesh_term>
	<mesh_term>Amino Acid Metabolism , Inborn Errors</mesh_term>
	<mesh_term>Vitamin B 12 Deficiency</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<criteria>genetically confirm CblC defect ; abstention antioxidant medication ( i.e . coenzyme Q10 , idebenone , vitamin E ) prior trial initiation throughout conduct trial . allergy EPI743 sesame oil ( screen test perform ) ; abnormal coagulation ; hepatic insufficiency Liver Function Tests great 2times normal value ; renal insufficiency require dialysis ; fat malabsorption preclude drug absorption .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Cobalamin C defect</keyword>
	<keyword>methylmalonic aciduria homocystinuria</keyword>
	<keyword>Visual function</keyword>
	<keyword>VEP</keyword>
	<keyword>ERG</keyword>
	<keyword>antioxidant drug</keyword>
</DOC>